PDX Core

项目总结/摘要 患者源性异种移植物（PDX）核心的主要目的是建立和表征PDX， 并支持UCaTS的两个综合研究项目的研究目标，一个与生物学相关的研究项目， PDX开发和试验中心（D-PDTC）。PDX核心将负责创建和 在免疫缺陷小鼠（NSG）中表征120个PDX模型，这些模型来自患有胃癌或胃癌的患者的肿瘤。 或肺癌，并在六个地点中的任何一个被诊断出来：五个NCI指定的综合癌症中心 (CCC)加州大学（UC）系统（戴维斯、洛杉矶、旧金山弗朗西斯科、欧文和圣地亚哥） 和德克萨斯大学西南CCC。所有新建立的PDX系都将来自肿瘤 根据我们预期的合并集水区，从代表种族/少数民族的患者中收集 为拉丁裔和亚裔美国人，夏威夷土著人/太平洋岛民（AANHPI）患者提供丰富的治疗。这些PDX 模型将用于产生特定个体荷瘤（PDX）小鼠的队列，用于药物功效和 差异研究。PDX核心将由经验丰富、有能力的专业人员和基础设施组成。 UCDCCC的共享资源（小鼠生物学共享资源[MBSR]和生物储存库共享 资源[BSR]。在过去的五年里，MBSR和BSR一直参与建立，维护， 表征、存储和分发来自人类患者的众多PDX模型和来自人类患者的PetDX模型。 在专用的、高度封闭的和无传染性病原体的环境中的兽医患者。具体地说， 在UCaMP期间，核心植入了383个不同的肿瘤，这些肿瘤经过传代，成功地建立了101个肿瘤。 模型中的大多数模型来自种族/民族社区的颜色。此外，由 聘用合格和有经验的人员，并在两个区域建立充分运作和随时可用的基础设施， 预先存在的共享资源，对赠款预算收取的唯一费用仅限于PDX建模 为这个项目服务。通过这种方式，PDX Core将成为成功开发PDX试验不可或缺的一部分 单药和药物组合的临床前试验策略，可切实导致临床 验证。PDX核心还将通过促进PDX的沉积，为PDX网络（PDXNet）做出贡献。 模型、肿瘤和数据输入弗雷德里克国家实验室的NCI患者衍生模型库 用于癌症研究，以便我们的模型除了共享之外还可以与更广泛的研究界共享 UCaTS成员之间的PDX。此外，PDX Core还将与PDXNet合作， 验证用于临床前试验的PDX模型开发和表征的SOP。

PROJECT SUMMARY/ABSTRACT The primary objectives of the Patient Derived Xenograft (PDX) Core will be to establish and characterize PDXs, and to support the research aims of the two integrated research projects of UCaTS, a disparity-relevant studies PDX Development and Trials Center (D-PDTC). The PDX Core will be responsible for the creation and characterization of 120 PDX models in immune-deficient mice (NSG) from tumors of patients with either gastric or lung cancers and diagnosed at any of the six sites: The five NCI designated comprehensive cancer centers (CCC) of the University of California (UC) system (Davis, Los Angeles, San Francisco, Irvine and San Diego) and the University of Texas Southwestern CCC. All of the newly established PDX lines will be from tumors harvested frompatients representing racial/ethnic minorities based on the combined catchment areas we expect to enrich for Latino and Asian American, Native Hawaiians/Pacific Islanders (AANHPI) patients. These PDX models will be used to generate cohorts of specific individual tumor-bearing (PDX) mice for drug efficacy and disparities studies. The PDX Core will consist of the expertise and infrastructure of experienced and capable shared resources at the UCDCCC (The Mouse Biology Shared Resource [MBSR] and the Biorepository Shared Resource [BSR]. Over the last five years, the MBSR and BSR have been involved in establishing, maintaining, characterizing, storing, and distributing numerous PDX models from human patients and PetDX models from veterinary patients in dedicated, highly-contained, and infectious pathogen-free environments. Specifically, during UCaMP, the core implanted 383 distinct tumors which were passaged to successfully establish 101 models in which the majority of models were derived from racially/ethnically communities of color. Further, by engaging qualified and experienced personnel and fully functioning and readily available infrastructure in two preexisting shared resources, the only costs charged to the grant budget are limited solely to PDX modeling services for this project. In this way, the PDX Core will be integral to the successful development of PDX trial strategies for preclinical testing of single agents and drug combinations that can feasibly lead to clinical validation. The PDX Core will also contribute to the PDX Network (PDXNet) by facilitating the deposition of PDX models, tumors, and data into the NCI Patient-Derived Models Repository at the Frederick National Laboratory for Cancer Research so that our models can be shared with the wider research community in addition sharing of the PDXs among UCaTS members. In addition, the PDX Core will also work with the PDXNet to develop and validate SOPs for development and characterization of PDX models for pre-clinical testing.